[Use of prodigioza in the overall treatment of chronic osteomyelitis].
Treatment of 188 patients suffering from chronic osteomyelitis of various etiology and localization with prodigiosan, a bacterial lipopolysaccharide favoured an increase in the nonspecific immunobiological reactivity: the phagocytic activity and leucocytic intensity increased, the average titers of iso- and heteroagglutinins, as well as the complementary activity of the serum became higher. The results of the clinico-laboratory studies are indicative of advisable use of prodigiosan in complex therapy of cases with chronic osteomyelitis.
D000328:Adult; D000373:Agglutinins / Q000032:analysis; D000910:Antibodies, Heterophile / Q000032:analysis; D000937:Antigen-Antibody Reactions; D002908:Chronic Disease; D003165:Complement System Proteins / Q000032:analysis; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007518:Isoantibodies / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010019:Osteomyelitis / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D011182:Postoperative Care; D011300:Preoperative Care; D011353:Prodigiosin / Q000008:administration & dosage / Q000627:therapeutic use*
D000373:Agglutinins; D000910:Antibodies, Heterophile; D007518:Isoantibodies; D003165:Complement System Proteins; D011353:Prodigiosin
Primenenie prodigiozana v kompleksnom lechenii khronicheskogo osteomielita